Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.
Prioritizing sibling over parental haploidentical donors may improve pediatric HCT outcomes
Bolaños-Meade J, et al., The Lancet Haematology – In a prospective, phase II trial, researchers found that tacrolimus, mycophenolate mofetil, with post-hematopoietic cell transplant (HCT) cyclophosphamide (TMMCy) produced the best GVHD-free, relapse-free survival (GRFS) for patients who received an allogeneic HCT when compared to the current standard of care.
Subscribe to E-News
Receive new research summaries monthly.